All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, What novel targeted therapies are currently under investigation for relapsed/refractory chronic lymphocytic leukemia (R/R CLL)?
What novel targeted therapies are currently under investigation for R/R CLL?
Tam summarizes key data on novel agents presented at ASCO, including TG-1701, an irreversible BTK inhibitor, and APG-2575, a selective BCL-2 inhibitor. He then presents the ELEVATE phase III trial, which compared acalabrutinib with ibrutinib in patients with R/R CLL.
ASCO 2016 | Poster Discussion - Small Molecule Therapy in Chronic Lymphocytic Leukemia
This poster discussion at ASCO 2016 was presented by Prof. Thorsten Zenz and focused on therapies using small molecular for Chronic Lymphocytic Leukemia.
The management of toxicities associated with targeted agents in CLL
The Lymphoma Hub is looking forward to hosting a virtual satellite symposium on the sequencing of therapies in high-risk relapsed/refractory (R/R) lymphoma and chronic lymphocytic...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox